Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi Opens Company’s First Digital Manufacturing Facility in Massachusetts

Paris-based Sanofi announced the inaugural opening of the company’s first new digital manufacturing facility for biologics production in Framingham, Massachusetts.

Read More »

Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

The U.S. Food and Drug Administration approved expanded use of Regeneron Pharmaceuticals Inc. and Sanofi SA’s eczema drug Dupixent to include patients aged between 12 and 17 years.

Read More »

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

Sanofi will pay Regeneron about $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body’s own immune system fight cancer.

Read More »

Late-stage Dupixent trials show positive results

Drugmakers Sanofi and Regeneron received positive results for Dupixent, which treats eczema and is seen as a key driver of future revenues.

Read More »

Regeneron CEO says fears over Eylea ‘greatly exaggerated‘

Fears of the demise of blockbuster eye drug Eylea were “greatly exaggerated,” Regeneron Pharmaceuticals Inc.’s chief executive said after the treatment and new eczema drug Dupixent powered the company’s fourth-quarter 2017 results.

Read More »

Dupixent Takes Another Step Toward Blockbuster Status

On Sept. 11, 2017, Regeneron Pharmaceuticals and Sanofi announced positive data for its Phase III LIBERTY ASTHMA QUEST trial of Dupixent (dupilumab) in asthma. Investors and analysts do not seem to agree on whether dupilumab is on its way to being one of the biggest blockbuster drugs in the last two years, or if it’s the most overhyped drug on the market.

Read More »

Regeneron Q2 2017 beats profit estimates

Regeneron Pharmaceuticals Inc.’s second-quarter 2017 profit handsomely beat estimates on strong demand for its flagship Eylea drug.

Read More »

Drug approvals bounce back in 2017

The number of new drugs approved for sale in United States and Europe has bounced back in 2017, suggesting a marked slowdown in 2016 was an aberration.

Read More »

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

Three of Europe’s top drugmakers face critical verdicts from U.S. regulators, with Sanofi and Roche likely to win approvals for two new products while GlaxoSmithKline braces for a potential generic rival.

Read More »

Novartis buys Ziarco, expands skin care portfolio

Novartis is buying privately held drugmaker Ziarco Group for an undisclosed sum to gain access to its investigational eczema medicine.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom